09/06/2026 US FDA approved a new every-eight week maintaince dosing option for Lilly’s lebrikizumab in moderate-to-severe atopic dermatitis US FDA accepted Takeda's application for Intravenous vedolizumab in Pediatric UC and CD US FDA approved a new every-eight week maintaince dosing option for Lilly’s lebrikizumab in moderate-to-severe atopic dermatitis (Ref) Eli lilly announced that the US FDA approved a regimen of one maintenance dose every eight weeks of a single injectio

01/06/2026 Vertex announced US FDA acceptance of BLA for accelerated approval of Povetacicept in IgA nephropathy Abivax announced Phase 3 maintenance results for obefazimod in moderately to severely active UC Vertex announced US FDA acceptance of BLA for accelerated approval of Povetacicept in IgA nephropathy (Ref) Vertex Pharmaceuticals announced that the US FDA had accepted its Biologics License Application (BLA) submission for povetacicept (anti-BAFF and APRIL) in adults w

18/05/2026 FDA approved IMMGOLIS™ and IMMGOLIS INTRI™ biosimilars for RA and UC FDA approved IMMGOLIS™ and IMMGOLIS INTRI™ biosimilars for RA and UC (Ref) Accord Biopharma announced that the US FDA had approved IMMGOLIS™ (golimumab-sldi) and IMMGOLIS INTRI™ (golimumab-sldi) biosimilar for rheumatoid arthritis (RA) and ulcerative colitis (UC). IMMGOLIS™ (golimumab-sldi), a biosimilar to Simponi® (golimumab), was approved for the treatment of adult patients with moderately to s

05/05/2026 J&J announced Phase 2b data from two studies in IBD J&J announced Phase 3 results for guselkumab in CD Avalo Therapeutics announced positive Phase 2 results for abdakibart in HS J&J announced Phase 2b data from two studies in IBD (Ref) Johnson & Johnson announced data from two Phase 2b studies, DUET-UC/ NCT05242484 and DUET-CD/ NCT05242471, which evaluated JNJ-4804 (IL-23 and TNF-α) in patients with moderately to severely active ulcerative colitis (UC) and Crohn’s

21/04/2026 FDA accepted application for Roche’s Gazyva for the treatment of SLE Cristcot announced FDA acceptance of NDA for ngHCA for treatment of UC of the Rectum AstraZeneca announced Phase 3 results for ravulizumab for IgA Nephropathy FDA accepted application for Roche’s Gazyva for the treatment of SLE ( Ref ) Roche announced that the US FDA had accepted a supplemental Biologics License Application (sBLA) for Gazyva®/Gazyvaro® (obinutuzumab; anti-CD20) for the treatment o

21/02/2026 Three-year data demonstrated sustained clinical and endoscopic remission in ulcerative colitis with guselkumab Three-year data demonstrated sustained clinical and endoscopic remission in ulcerative colitis with guselkumab ( Ref ) Johnson & Johnson announced new long-term data from the Phase 2b/3 QUASAR/ NCT04033445 study evaluating TREMFYA® (guselkumab; anti-IL-23) in adult patients with moderately-to-severely active ulcerative colitis (UC) In this study, guselkuma

17/02/2026 Sanofi and Teva’s duvakitug Phase 2b maintenance data demonstrated clinically meaningful durable efficacy in UC and CD Nektar Therapeutics announced a research collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165 in multiple sclerosis Sanofi and Teva’s duvakitug Phase 2b maintenance data demonstrated clinically meaningful durable efficacy in UC and CD ( Ref ) Sanofi and Teva announced positive results from the Phase 2b RELIEVE UCCD LTE/NCT05668013 study of